Literature DB >> 3014692

Elimination of infectious retroviruses during preparation of immunoglobulins.

G Mitra, M F Wong, M M Mozen, J S McDougal, J A Levy.   

Abstract

Safety concerns for immunoglobulin preparations have led us to study partition/inactivation of two prototype retroviruses, mouse xenotropic type C and lymphadenopathy-associated virus (LAV) of the acquired immunodeficiency syndrome (AIDS), during manufacture and storage of immunoglobulins. Reduction of infectious retrovirus titers were 10(5) to 10(8)-fold through Cohn-Oncley cold ethanol fractionation from plasma to fraction II, 10(3) to 10(5)-fold through incubation at pH 4.0 and another 10(4)-fold through incubation of the purified liquid immunoglobulin preparations at 27 degrees C or 45 degrees C. The results support the clinical and epidemiological evidence that therapeutic immunoglobulin preparations do not transmit AIDS virus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014692     DOI: 10.1046/j.1537-2995.1986.26486262753.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 3.  Newer uses of intravenous immunoglobulins as anti-infective agents.

Authors:  J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Intravenous immune globulin use in children. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-01-15       Impact factor: 8.262

5.  The clinical use of intravenous immunoglobulin in pediatrics.

Authors:  V Wahn
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

Review 6.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 7.  Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies.

Authors:  H M Chapel
Journal:  BMJ       Date:  1994-02-26

8.  Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Authors:  Richard L Wasserman; Joseph A Church; Mark Stein; James Moy; Martha White; Steven Strausbaugh; Harry Schroeder; Mark Ballow; James Harris; Isaac Melamed; David Elkayam; William Lumry; Daniel Suez; Syed M Rehman
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

Review 9.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

10.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.